Cite
HARVARD Citation
Cascinu, S. et al. (n.d.). 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). European journal of cancer. 51 (3), pp. S329-. [Online].